Recent studies show that new obesity drugs, manufactured by Orexigen Therapeutics, Novo Nordisk, and VIVUS, can help patients lose weight.
Novo Nordisk, Eli Lilly, MannKind, and Medtronic are changing how we treat diabetes with better insulin, newer drugs, and wearable medical devices. Let’s take a look at their greatest accomplishments.
Glaxo announced that the FDA has eased the restrictions on Avandia use.
Is Novo Nordisk's (NYSE: NVO) diabetes treatment-focused strategy wise, or should the company diversify?
AstraZeneca and Bristol-Myers announced that Xigduo has received a positive opinion from the Committee for Medicinal Products for Human Use.
Despite a bumpy 2013, largely caused by the FDA rejection of its drug Tresiba, is Novo Nordisk a stock to add to your watchlist?
Novo Nordisk received a positive opinion from the CHMP under the EMA regarding NovoRapid PumpCart
Eli Lilly, Johnson & Johnson, and Pfizer have failed to treat Alzheimer’s disease despite their very high-profile efforts. Could these three alternative treatments be the answer, and will they pull companies like Novo Nordisk and Amgen into the market as well?
The FTSE Portugal 20 ETF makes it easy, but there are still risks.
Investors without a deep-value bias might want to consider these.
Eli Lilly will invest more than $700 million to boost its insulin manufacturing capacity in Puerto Rico, France, China and the United States.
Roche received positive news when the U.S. Food and Drug Administration (FDA) approved another drug, Gazyva (obinutuzumab), for the treatment of CLL.
Afrezza could become the first blockbuster inhaled insulin product.
Why hasn't Novo Nordisk, the world's largest manufacturer of insulin, gone anywhere over the past year?